Avid Bioservices, Inc.
Avid Bioservices, Inc.（CDMO）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
cdmo · 股价预测 · 10 位分析师（近3月）· FMP · 更新于 2026年6月4日
分析师评级与共识
基于过去 3 个月内 10 位华尔街分析师
Buy
10 位分析师
共识
评级分布
12 个月目标价
High
$8.00
Consensus
$8.00
-35.9% upside
Low
$8.00
Median: $8 · Last Close: $12.49
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $12.49 | ↓ 0.03% |
1-day model range: $12.48–$12.49. Peak: $12.49 (-0.03%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $11 | -12.2% |
| 2028 | $10 | -18.1% |
| 2029 | $10 | -21.1% |
| 2030 | $10 | -22.7% |
| 2031 | — | -23.5% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CDMO · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-11-07 | RBC Capital | Downgrade ↓ | Outperform→Sector Perform |
| 2024-09-10 | RBC Capital | Maintains | Outperform→Outperform |
| 2024-09-10 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2024-07-03 | RBC Capital | Maintains | Outperform→Outperform |
| 2024-04-30 | RBC Capital | Maintains | Outperform→Outperform |
| 2024-03-11 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2024-03-07 | RBC Capital | Maintains | Outperform→Outperform |
| 2023-12-08 | Craig-Hallum | Maintains | Buy→Buy |
| 2023-12-08 | Keybanc | Maintains | Overweight→Overweight |
| 2023-12-08 | RBC Capital | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Avid Bioservices, Inc. (CDMO) stock. Of the recent 49 rating actions, 7 were upgrades and 6 were downgrades. 10 analysts currently cover CDMO.
分析师推荐趋势
CDMO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$163M
↓ 27.5% YoY
Revenue Next Year
$190M
↑ 16.8% YoY
EPS This Year
$-0.38
EPS Next Year
$-0.11
↓ 70.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast CDMO EPS of $-0.38 for the current fiscal year, based on estimates from 1 analysts. The CDMO revenue forecast is $163M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
CDMO 股价预测由两类独立数据源支撑：来自 10 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CDMO 的共识目标价为 $8.00（-35.9% 上行空间），分析师共识为 Buy。
CDMO 的短期预测（明日）为 $12.49（-0.03%）。 CDMO 对 2027 年的股价预测均值为 $11。 CDMO 对 2030 年的预测区间为 $10–$10。
Avid Bioservices, Inc. 在 NASDAQ 上市，代码 CDMO。CDMO 在 2027 年的整体展望偏积极，在覆盖分析师中约 90% 对应 Buy 共识。
常见问题
CDMO 预测 · 8 个问题根据 10 位华尔街分析师，CDMO 的 12 个月平均目标价为 $8.00，最高 $8.00、最低 $8.00。若有图表，中位目标价可在上方查看。相对当前价 $12.49，隐含约 -35.9% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.